Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

Fineline Cube Oct 28, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...

Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

Fineline Cube Oct 28, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China

Fineline Cube Oct 27, 2024

RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...

Company Medical Device

Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment

Fineline Cube Oct 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...

Company Drug

Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center

Fineline Cube Oct 26, 2024

On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...

Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs

Fineline Cube Oct 26, 2024

TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...

Policy / Regulatory

Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024

Fineline Cube Oct 25, 2024

The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...

Company Drug

BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy

Fineline Cube Oct 25, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...

Company

Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion

Fineline Cube Oct 25, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...

Company

Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China

Fineline Cube Oct 25, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...

Company Drug

Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area

Fineline Cube Oct 25, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment

Fineline Cube Oct 25, 2024

The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...

Company Deals

AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets

Fineline Cube Oct 25, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...

Company Drug

Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors

Fineline Cube Oct 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...

Company Drug

Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer

Fineline Cube Oct 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Drug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus

Fineline Cube Oct 25, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...

Policy / Regulatory

China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding

Fineline Cube Oct 25, 2024

The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...

Company Drug

Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria

Fineline Cube Oct 25, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...

Company Deals

3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong

Fineline Cube Oct 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...

Policy / Regulatory

China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation

Fineline Cube Oct 25, 2024

The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...

Posts pagination

1 … 219 220 221 … 606

Recent updates

  • Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion
  • Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset
  • Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
  • Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.